Global epidemiology of hepatitis C virus infection (Q27860799)

Prevalence of antibodies against hepatitis C virus in the adult German population.

Europe PubMed Central

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Prediction of hepatitis C burden in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Iatrogenic GB virus C/hepatitis G virus infection in an area endemic for hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Massive sero-epidemiological survey of hepatitis C virus: clustering of carriers on the southwest coast of Tsushima, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Detection of HCV RNA in subjects with antibody to hepatitis C virus among the general population of Fukuoka, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Occupational hepatitis C virus infection in Italian health care workers. Italian Study Group on Occupational Risk of Bloodborne Infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C virus infection in the general population: a community-based study in West Bengal, India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Prevalence of hepatitis B and C viruses in healthy Indonesian blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Commentary: Modelling the epidemiology of hepatitis C and its complications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Case-reporting of acute hepatitis B and C among injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Modeling the hepatitis C virus epidemic in France

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Epidemiology of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Epidemiology of hepatitis C: geographic differences and temporal trends

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Incident hepatitis C virus infection in a community-based population in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Epidemiology of hepatitis C virus infection in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Correlates of hepatitis C virus infections among injection drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Evidence of patient-to-patient transmission of hepatitis C virus through contaminated intravenous anaesthetic ampoules

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

The global burden of disease attributable to contaminated injections given in health care settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis B, C and human immunodeficiency virus infections in multiply-injected kala-azar patients in Delhi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Differences in Risk Factors for Being Either a Hepatitis B Carrier or Anti-Hepatitis C+ in a Hepatoma-Hyperendemic Area in Rural Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

High rate of hepatitis C virus infection in an isolated community: persistent hyperendemicity or period-related phenomena?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Rapid assessment of injection practices in Mongolia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Current and emerging infectious risks of blood transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Va cooperative study of post-transfusion hepatitis, 1969-1974: incidence and characteristics of hepatitis and responsible risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Blood safety in the developing world and WHO initiatives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Blood banking in China

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Estimated risk of HIV transmission by blood transfusion in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Availability, safety, and quality of blood for transfusion in the Americas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Safety of blood supply for infectious diseases in Latin American countries, 1994-1997

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Transfusion-associated hepatitis in a tertiary referral hospital in India. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Residual risk of transfusion in Ghana

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C in hospital employees with needlestick injuries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Mother-to-infant transmission of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent Region (UK).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C and HIV-1 coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C and progression of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C in an urban population infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Hepatitis C Virus Infection in a Human Immunodeficiency Virus‐Positive Cohort in Hawaii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Nosocomial outbreak of multiple bloodborne viral infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Characteristics of patients with dual infection by hepatitis B and C viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Chronic liver disease mortality attributable to hepatitis B and C in New Zealand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Clinical course of hepatitis C virus during the first decade of infection: cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

The global distribution of average volume of alcohol consumption and patterns of drinking

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Chronic liver disease mortality in the United States, 1979 through 1989

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Chronic liver disease mortality in the United States, 1990-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Trends in primary liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Epidemiology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Epidemiology, risk factors, and natural history of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Estimating future hepatitis C morbidity, mortality, and costs in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Global epidemiology and burden of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

The cost of hepatitis C and the cost–effectiveness of its prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

Simulation of hepatitis C based on a mandatory reporting system.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970216-4

7 January 2021

10.1016/S1473-3099(05)70216-4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

16122679

1 reference

Consolidated OpenCitations Corpus – April 2017